This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AVDL Avadel Pharmaceuticals (AVDL) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Avadel Pharmaceuticals Stock (NASDAQ:AVDL) Get Avadel Pharmaceuticals alerts:Sign Up Key Stats Today's Range$21.63▼$21.7650-Day Range$21.39▼$21.6952-Week Range$8.19▼$23.57Volume35.02 million shsAverage Volume2.03 million shsMarket Capitalization$2.09 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingReduce Company Overview Avadel Pharmaceuticals plc is a global specialty biopharmaceutical company focused on developing and delivering treatments for rare diseases and central nervous system disorders. Headquartered in Dublin, Ireland, with operations in the United States, Avadel’s portfolio centers on sleep disorder therapeutics, including its flagship low-sodium oxybate product, XYWAV, which is approved in the U.S. for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy. The company is also advancing FT218, a once-nightly formulation of sodium oxybate, currently under regulatory review for narcolepsy management. Formed through a rebranding of Flamel Technologies in 2016 and a strategic shift toward rare disease drug development, Avadel has built its R&D capabilities around improving patient compliance and reducing daily sodium exposure compared to traditional therapies. Its clinical pipeline spans multiple indications within sleep medicine, aiming to address unmet needs such as idiopathic hypersomnia and other central nervous system conditions. Avadel conducts its research and commercialization activities primarily in North America and Europe, leveraging a network of partnerships and specialty distributors to bring its therapies to patients. The company’s manufacturing sites are strategically located to support both clinical supply and commercial production, and it operates under the regulatory standards set by the U.S. Food and Drug Administration and the European Medicines Agency. Through collaborations with academic centers, patient advocacy groups, and contract research organizations, Avadel continues to expand its expertise in orphan drug development. The company’s leadership team comprises seasoned pharmaceutical executives and scientists dedicated to advancing therapeutic solutions that improve quality of life for patients with rare and complex disorders.AI Generated. May Contain Errors. Read More Receive AVDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AVDL Stock News HeadlinesForm 8.3 - Avadel Pharmaceuticals plcFebruary 12, 2026 | globenewswire.comForm 8.3 -Avadel Pharmaceuticals plcFebruary 11, 2026 | globenewswire.comManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 in one quarter. Institutions own about 83% of shares, including BlackRock's 32 million shares worth $716 million and Vanguard's 48 million shares worth nearly $1.1 billion. A new multi-year deal with Palantir adds an AI-driven edge to this energy producer's operations.November 20 at 1:00 AM | Monument Traders Alliance (Ad)Avadel Pharmaceuticals Announces Outcome of the Court Sanction HearingFebruary 10, 2026 | globenewswire.comForm 8.3 -Avadel Pharmaceuticals plcFebruary 10, 2026 | globenewswire.comForm 8.3 -Avadel Pharmaceuticals plcFebruary 9, 2026 | globenewswire.comForm 8.3 -Avadel Pharmaceuticals plcFebruary 6, 2026 | globenewswire.comForm 8.3 -Avadel Pharmaceuticals plcFebruary 5, 2026 | globenewswire.comSee More Headlines AVDL Stock Analysis - Frequently Asked Questions How were Avadel Pharmaceuticals' earnings last quarter? Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) issued its earnings results on Tuesday, November, 4th. The company reported $0.00 earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by $0.04. Avadel Pharmaceuticals's revenue for the quarter was up 55.0% on a year-over-year basis. What other stocks do shareholders of Avadel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avadel Pharmaceuticals investors own include Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), NVIDIA (NVDA), ADMA Biologics (ADMA), Bank of America (BAC), Advanced Micro Devices (AMD) and Plug Power (PLUG). Company Calendar Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (17m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 AVDL's financial health is in the Green zone, according to TradeSmith. AVDL has been in this zone for over 17 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AVDL CIK1012477 Webwww.avadel.com Phone(531) 901-5201Fax353-1526-1077Employees70Year Founded2015Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$48.83 million Net Margins-0.11% Pretax Margin-1.31% Return on Equity-0.33% Return on Assets-0.15% Debt Debt-to-Equity RatioN/A Current Ratio2.76 Quick Ratio2.37 Sales & Book Value Annual Sales$248.52 million Price / Sales8.41 Cash FlowN/A Price / Cash FlowN/A Book Value$0.77 per share Price / Book27.78Miscellaneous Outstanding Shares97,657,000Free Float92,579,000Market Cap$2.09 billion OptionableOptionable Beta1.31 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:AVDL) was last updated on 2/12/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored6 Men Secretly Changed America’s Money. Now It’s Happening AgainIn 1910, six powerful men secretly met to lay the groundwork for the Federal Reserve, reshaping America's fina...Banyan Hill Publishing | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avadel Pharmaceuticals PLC. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avadel Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.